Current Press

ProPhase Stock Quote

2017 ProPhase Labs Annual Report

ProPhase Labs, Inc. to Release Third Quarter Results on Wednesday, November 10

11-03-2010 22:54:52Press Release

DOYLESTOWN, PA -- November 3, 2010 - ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the third quarter, ended September 30, 2010, will be released before market open on Wednesday, November 10, 2010. A conference call will be held later that morning on November 10th, at 11:00am EDT. ProPhase Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a Company overview including a review of activities and third quarter results. There will be a question and answer session following initial remarks.

Participants wishing to ask questions may access the live call by dialing (877) 217– 6026 conference ID # 21186139. A replay of the conference call will be available for 90 days on the Company web site at www.ProPhaseLabs.com.

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA approved facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. The joint venture will formulate and test products to exploit market opportunities within ProPhase's robust OTC distribution channels.